Infectious Diseases (all articles)
[Preprint] PRINCIPLE RCT: Colchicine does not improve time to recovery in outpatients with Covid-19 at higher risk of complications.
24 Sep, 2021 | 10:13h | UTC
Commentary on Twitter
While COLCORONA trial found limited evidence that colchicine may reduce COVID-19 related hospitalisation/death
🆕💥💥@TrialPrinciple preprint
Colchicine did NOT improve time to recovery in people at higher risk of complications w COVID-19 in the communityhttps://t.co/2sUoeD7sGV pic.twitter.com/fi2THbxewW— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) September 23, 2021
Just how do deaths due to COVID-19 stack up?
24 Sep, 2021 | 10:07h | UTCJust How Do Deaths Due to COVID-19 Stack Up? – Think Global Health
Commentary on Twitter
How do deaths due to COVID-19 compare? Despite a likely undercount in many places, COVID is the leading killer in most of Latin America & Western Europe, says Chris Troeger @IHME_UW. Our interactive map ranks #COVID deaths among all causes since Jan 2020.https://t.co/U8J1uWUsgK
— Think Global Health (@ThinkGlobalHlth) September 23, 2021
How patient data underpin COVID-19 research – “Tracking the coronavirus SARS-CoV-2, developing treatments and testing vaccines have relied on access to the health data of millions of people. This massive trove could be used to understand other diseases, but not everyone is convinced”.
24 Sep, 2021 | 10:03h | UTCHow patient data underpin COVID-19 research – Nature
No, vaccinated people are not ‘just as likely’ to spread the Coronavirus as unvaccinated people.
24 Sep, 2021 | 10:06h | UTC
Commentary on Twitter
“Vaccinated people are just as likely to spread the coronavirus.”
This isn't true. But some people — even some very smart people — mistakenly believe this.
Dr. @Craig_A_Spencer explains here why, in this really good piece from @TheAtlantic.https://t.co/9D1dngt3oG
— Paul Sax (@PaulSaxMD) September 23, 2021
WHO recommends antibody treatment for COVID patients at high risk of hospital admission.
24 Sep, 2021 | 10:11h | UTCOriginal article and infographic: A living WHO guideline on drugs for covid-19 – The BMJ
COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants.
24 Sep, 2021 | 10:02h | UTCCOVID-19 vaccines: Keeping pace with SARS-CoV-2 variants – Cell
Commentary on Twitter
https://twitter.com/Sri_Baqri/status/1438865999281983490
Review | Interplay between endocrinology, metabolism, and COVID-19 infection.
24 Sep, 2021 | 10:00h | UTCInterplay between endocrinology, metabolism, and COVID-19 infection – Clinical Medicine Journal
RCT confirms antibiotics are not needed for most children with uncomplicated lower respiratory tract infection if pneumonia is not suspected clinically.
24 Sep, 2021 | 09:00h | UTC
Commentary on Twitter
#Antibiotic resistance is a global public health threat.
New trial indicates, unless pneumonia is suspected, clinicians should provide safety-netting advice but not prescribe antibiotics for most children presenting with chest infections. https://t.co/mOwLG5rZd1 #AMR pic.twitter.com/b0c7Z5flQk
— The Lancet (@TheLancet) September 23, 2021
WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017–18 – In many countries, ciprofloxacin resistance was exceedingly high, and decreased susceptibility or resistance to ceftriaxone and cefixime continued to emerge.
24 Sep, 2021 | 08:53h | UTC
[Preprint] Third dose of Sinopharm inactivated SARS-CoV-2 vaccine induces robust B and T cell responses.
23 Sep, 2021 | 10:18h | UTCCommentaries:
Sinopharm’s COVID booster reverses antibody decline, enhances cell-based responses – study – Reuters
Randomized phase 1/2 trial: Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in children and adolescents aged 3–17 years.
23 Sep, 2021 | 10:16h | UTC
‘Not a zero-sum game’: Sharing vaccines is in countries’ best interests.
23 Sep, 2021 | 10:09h | UTC‘Not a zero-sum game’: Sharing vaccines is in countries’ best interests – YaleNews
Original article: National interest may require distributing COVID-19 vaccines to other countries – Scientific Reports
Commentary on Twitter
"when US has reached the threshold for domestic herd immunity, it would be optimal to donate doses to other countries, as this would allow for a sharp reduction in the inflow of infected individuals from abroad"
– Modeling by @SaadOmer3, @amynmalik & co https://t.co/NFfp39tde6— Mushfiq Mobarak (@mushfiq_econ) September 16, 2021
Systematic review: Clinical characteristics of multisystem inflammatory syndrome in adults.
23 Sep, 2021 | 10:12h | UTC
Commentary on Twitter
Multisystem inflammatory syndrome has been reported in adults worldwide but may be hard to distinguish from acute biphasic #COVID19 and postacute sequelae of COVID-19. More research is needed to understand this emerging clinical entity. https://t.co/OnerzsZKVB
— JAMA Network Open (@JAMANetworkOpen) September 22, 2021
The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable.
23 Sep, 2021 | 10:08h | UTC
Commentary on Twitter
Flaws in ivermectin data suggest that COVID-19 meta-analyses need rethinking
Correspondence from Jack Lawrence @GidMK @K_Sheldrick and colleagues https://t.co/lUqXX9DQjO pic.twitter.com/Oh848X1VGv
— Nature Medicine (@NatureMedicine) September 22, 2021
Perspective | Sorry, a Coronavirus Infection Might Not Be Enough to Protect You – “Anyone who’d rather have COVID-19 than get vaccinated is taking two gambles: that immunity will stick around, and that symptoms won’t”.
22 Sep, 2021 | 10:23h | UTCSorry, a Coronavirus Infection Might Not Be Enough to Protect You – The Atlantic
[Press release – not published yet] J&J says booster shot at two months provided 75% protection against moderate to severe COVID-19 globally and 94% of such cases in the U.S.
22 Sep, 2021 | 10:26h | UTCCommentaries:
Johnson & Johnson says additional dose boosts Covid vaccine efficacy – STAT
J&J booster 94% effective against severe COVID, company says – CIDRAP
Two dose version of Johnson & Johnson shot 94% effective against Covid-19, study finds – CNN
Commentaries on Twitter
(thread – click for more)
📍BREAKING—At last—new data on 2-doses of Johnson & Johnson's #vaccine (doses 56 days apart) is 94% effective against symptomatic #COVID19, thus comparable to Moderna/Pfizer. And 100% effective against severe COVID. Booster for 1 dose works well too. 🧵https://t.co/3nPkodOjuG pic.twitter.com/DizjWt9NYX
— Eric Feigl-Ding (@DrEricDing) September 21, 2021
(thread – click for more)
https://twitter.com/hildabast/status/1440363761299124229
[Preprint] SARS-like viruses may jump from animals to people hundreds of thousands of times a year.
22 Sep, 2021 | 10:22h | UTCSARS-like viruses may jump from animals to people hundreds of thousands of times a year – Science
Original study: A strategy to assess spillover risk of bat SARS-related coronaviruses in Southeast Asia – medRxiv
Related:
Did the coronavirus jump from animals to people twice? – Nature
The Origins of SARS-CoV-2: A Critical Review.
Fauci says natural origins theory of coronavirus is still the most likely.
Interpreting SARS-CoV-2 Test Results.
22 Sep, 2021 | 10:24h | UTCInterpreting SARS-CoV-2 Test Results – JAMA
Long Covid – The illness narratives.
22 Sep, 2021 | 10:19h | UTCLong Covid – The illness narratives – Social Science & Medicine
Commentary on Twitter
https://twitter.com/trishgreenhalgh/status/1439199576158883843
The fight to manufacture COVID vaccines in lower-income countries.
22 Sep, 2021 | 10:21h | UTCThe fight to manufacture COVID vaccines in lower-income countries – Nature
RCT: Probiotics do not reduce the incidence of ventilator-associated pneumonia in critically ill patients.
22 Sep, 2021 | 10:03h | UTCEffect of Probiotics on Incident Ventilator-Associated Pneumonia in Critically Ill Patients: A Randomized Clinical Trial – JAMA (free for a limited period)
Commentary: Probiotic Flops for Ventilator-Associated Pneumonia Prevention – MedPage Today (free registration required)
Cluster RCT: Procalcitonin point-of-care testing may reduce antibiotic prescription for patients with suspected lower respiratory tract infection in primary care.
22 Sep, 2021 | 10:01h | UTC
Cluster RCT: Implementing C reactive protein point-of-care testing in nursing homes may reduce antibiotic prescribing for suspected lower respiratory tract infections.
22 Sep, 2021 | 10:02h | UTC
[Press release – not published yet] Pfizer announces COVID-19 vaccine in children 5 to 11 years produced strong neutralizing antibody responses.
21 Sep, 2021 | 09:57h | UTCCommentaries:
Pfizer says COVID-19 vaccine safe, effective in younger children – CIDRAP
Commentaries on Twitter
I'm so glad to see that Pfizer has data to submit for their vaccine for 5-11 year olds. But any strong assertions about safety, such as for low incidence side-effects like myocarditis, cannot made from a trial of ~1500 children.
— Eric Topol (@EricTopol) September 20, 2021
(thread – click for more)
BREAKING NEWS: Pfizer releases results of 5-11 year old trial for its vaccine. 2-dose 10 microgram regimen (Pfizer uses 30 mcg for 12 and up) administered 21 days apart (sigh, we now know we need longer duration between doses for better effectiveness)https://t.co/43MHnlZgqg
— Monica Gandhi MD, MPH (@MonicaGandhi9) September 20, 2021
(thread – click for more)
https://twitter.com/hildabast/status/1439976038964940803
M-A: Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19 – According to this analysis, standard-dose prophylactic anticoagulation should be the standard of care for hospitalized patients with COVID-19 who do not have an indication for therapeutic anticoagulation, irrespective of disease severity.
21 Sep, 2021 | 09:54h | UTC
Commentary on Twitter (thread – click for more)
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with #COVID-19: A systematic review and meta-analysis of randomized controlled trials https://t.co/Gkdfp9vn75 @ESC_Journals @escardio @ESCardioNews #COVID19
— Luis Ortega Paz (@Ortega_Paz) September 15, 2021